TITLE

Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding

AUTHOR(S)
Tsai, Yi-Wen; Wen, Yu-Wen; Huang, Weng-Foung; Chen, Pei-Fen; Kuo, Ken; Hsiao, Fei-Yuan
PUB. DATE
January 2011
SOURCE
Journal of Gastroenterology;Jan2011, Vol. 46 Issue 1, p39
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Concomitant use of antiplatelet agents and proton-pump inhibitors (PPIs) has been recommended in patients with a history of gastrointestinal (GI) hemorrhage. However, recent studies have reported that PPIs may alter clopidogrel's pharmacokinetics and potentially lead to an increased risk of recurrent adverse cardiovascular (CV) events. Methods: Using Taiwan's 2000-2006 National Health Insurance database, this population-based retrospective cohort study assessed CV and GI events in patients who had a prior history of GI bleeding and had been prescribed ongoing antiplatelet therapy after acute coronary syndrome (ACS) discharge. We identified 3,580 ACS patients and categorized them into (1) those taking clopidogrel alone, (2) those taking clopidogrel plus PPIs, and (3) those taking aspirin plus PPIs. Cox proportional hazards models were used to assess the association between the use of antiplatelet therapies and CV/GI events. Results: The clopidogrel only group and the clopidogrel plus PPI group were found to be at lower risk for GI events than the aspirin plus PPI group [adjusted hazard ratio (HR) 0.23 (95% confidence interval; CI 0.14-0.36) and HR 0.70 (0.52-0.96), respectively]. However, while the clopidogrel only group had a lower risk of CV events than the aspirin plus PPI group [HR 0.57 (0.38-0.84)], the clopidogrel plus PPI group had a significantly higher CV risk than the aspirin plus PPI group [HR 1.59 (1.18-2.13)]. Conclusions: Our findings suggest that although the use of clopidogrel plus PPIs provides GI benefits, with this treatment, there is an increased CV risk among patients with a history of GI bleeding.
ACCESSION #
57318918

 

Related Articles

  • Prescribing antiplatelets. Morris, David // Independent Nurse;1/18/2010, p23 

    The article discusses the use of antiplatelet agents in the prevention of cardiovascular disease (CVD). It cites the four oral antiplatelet agents that are being used in Great Britain, namely, aspirin, clopidogrel, dipyridamole and prasugrel. It also examines the use of low dose aspirin combined...

  • Influence of different proton pump inhibitors on platelet function in acute myocardial infarction patients receiving clopidogrel treatment after percutaneous coronary intervention. Zhe Wang; Xinchun Yang; Jun Cai; Mulei Chen; Xinhong Wan // Biomedical Research (0970-938X);2013, Vol. 24 Issue 4, p453 

    The objective of the present study is to investigate the effect of clopidogrel and proton pump inhibitors (PPIs) on upper gastrointestinal bleeding and adverse cardiovascular events in acute myocardial infarction (MI) patients after percutaneous coronary intervention (PCI). A total of 240...

  • Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. Lanas, Angel; Gargallo, Carla // Journal of Gastroenterology;Jun2015, Vol. 50 Issue 6, p626 

    Low-dose aspirin, alone or combined with other antiplatelet agents, is increasingly prescribed for cardiovascular prevention. However, the cardiovascular benefits should be evaluated together with the gastrointestinal risks. Low-dose aspirin is associated with upper and lower gastrointestinal...

  • Interactions Between Clopidogrel and Proton Pump Inhibitors: A Review of Evidence. Muñoz-Esparza, C.; Jover, E.; Hernández-Romero, D.; Saura, D.; Valdés, M.; Lip, G. Y. H.; Marín, F. // Current Medicinal Chemistry;Jun2011, Vol. 18 Issue 16, p2386 

    No abstract available.

  • Proton Pump Inhibitors and the Prevention of Recurrent GI Bleed in Patients Treated with Clopidogrel. Oyetayo, O.O.; Farris, C.A.; Wahawisan, J. // Clinical Medicine Insights: Therapeutics;2012, Issue 4, p9 

    Clopidogrel is an antiplatelet agent indicated in the management of atherothrombotic conditions. Bleeding is a predictable adverse event associated with antiplatelet agents. While non-ulcerogenic; a major site of bleeding with clopidogrel is the gastrointestinal (GI) tract. The risk of GI...

  • Clopidogrel and aspirin. Elliott, William T. // Infectious Disease Alert;Jun2010 Supplement, p2 

    The article discusses the results of a study which examined the optimal duration of the use of dual antiplatelet therapy with clopidogrel and aspirin in patients who had received drug-eluding stents.

  • Entfernung eines Periduralkatheters unter dualer Antiplättchentherapie nach akutem Koronarsyndrom. Limper, U.; Lynch, J. // Anaesthesist;Aug2012, Vol. 61 Issue 8, p686 

    This article reports the case of a patient who developed acute coronary syndrome while receiving postoperative pain treatment via an epidural catheter (EC). Platelet function testing was performed before removal of the EC to assess the bleeding risk under ongoing dual antiplatelet therapy....

  • Clopidogrel and Proton Pump Inhibitors: Is There a Significant Drug-Drug Interaction? Shmulevich, Emilia; Friger, Michael; Gilutz, Harel; Azab, Abed N. // Canadian Journal of Cardiovascular Nursing;2011, Vol. 21 Issue 4, p27 

    Dual antiplatelet therapy with aspirin and clopidogrel is among the most efficacious treatment for patients after acute coronary syndromes and for those who have had a percutaneous coronary intervention and coronary stent implantation. Patients who are treated with dual antiplatelet therapy are...

  • Interaction Between Clopidogrel and Proton Pump Inhibitors: Hypothesis to Explain Multifactorial CYP2C19 Inhibition. Huixia Zhang; Ragueneau-Majlessi, Isabelle; Levy, Rene H. // Drug Metabolism Letters;Dec2009, Vol. 3 Issue 4, p287 

    Clopidogrel is an antiplatelet drug that requires bioactivation to its active metabolite to demonstrate its antiplatelet effect. Formation of the active metabolite involves multiple cytochrome P450 enzymes, with CYP2C19 playing an important role. Clopidogrel is often co-administered with proton...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics